International Journal of Antimicrobial Agents
Volume 23, Issue 6 , Pages 533-546 , June 2004

Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin

  • P.C Appelbaum

      Affiliations

    • Department of Pathology, Hershey Medical Center, P.O. Box 850, Hershey, PA 17033, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-717-531-5113; fax: +1-717-531-7953.
    • ,
  • S.H Gillespie

      Affiliations

    • Centre for Medical Microbiology, Royal Free and University College Medical School Royal Free Campus, London, NW3 2PF, UK
    • ,
  • C.J Burley

      Affiliations

    • Carol Burley Associates, P.O. Box 2612, Bourne End, SL8 5ZJ, UK
    • ,
  • G.S Tillotson

      Affiliations

    • Public Health Research Institute, 225 Warren Street, Newark, NJ 07303, USA

References 

  1. Minino AM, Arias E, Kochanek KD, Murphy SL, Smith BL. Deaths: Final Data for 2000. National vital statistics reports, vol. 50. Hyattsville, Maryland: National Center for Health Statistics; 2002.
  2. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance—United States, 1971–2000. Respir. Care. 2002;47:1184–1189
  3. Hall MJ, Owings MF, 2000. National Hospital Discharge Survey. Advance data from vital and health statistics. Hyattsville, Maryland: National Center for Health Statistics; 2002.
  4. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin. Ther. 1998;20:820–837
  5. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. Treatment cost of acute exacerbations of chronic bronchitis. Clin. Ther. 1999;21:576–591
  6. Kislak JW, Razavi LM, Daly AK, Finland M. Susceptibility of pneumococci to nine antibiotics. Am. J. Med. Sci. 1965;250:261–268
  7. Hansman D, Glasgow H, Sturt J, Devitt L, Douglas R. Increased resistance to penicillin of pneumococci isolated from man. N. Engl. J. Med. 1971;284:175–177
  8. Schito GC, Debbia EA, Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project. J. Antimicrob. Chemother. 2000;46(Topic T1):3–9
  9. Jacobs MR, Koornhof HJ, Robins-Browne RM, et al.  Emergence of multiply resistant pneumococci. N. Engl. J. Med. 1978;299:735–740
  10. Whitney CG, Farley MM, Hadler J, et al.  Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N. Engl. J. Med. 2000;343:1917–1924
  11. Marston BJ, Plouffe JF, File TM, et al.  Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Arch. Intern. Med. 1997;157:1709–1718
  12. Mundy LM, Auwaerter PG, Oldach D, et al.  Community-acquired pneumonia: impact of immune status. Am. J. Respir. Crit. Care Med. 1995;152:1309–1315
  13. Fang GD, Fine M, Orloff J, et al.  New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine. 1990;69:307–316
  14. Lim WS, Macfarlane JT, Boswell TCJ, et al.  Study of community-acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax. 2001;56:296–301
  15. Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev. Infect. Dis. 1989;11:586–599
  16. Lagerström F, Bader M, Foldevi M, Fredlund H, Nordin-Olsson I, Holmberg H. Microbiological etiology in clinically diagnosed community-acquired pneumonia in primary care in Örebro. Sweden Clin. Microbiol. Infect. 2003;9:645–652
  17. Chodosh S. Bronchitis and asthma. In: Gorbach SL, Bartlett JG, Blacklow NR, editors. Infectious diseases. Philadelphia: WB Saunders; 1992. p. 476–85.
  18. Lindsay G, Scorer HJN, Carnegie CMD. Safety and efficacy of temafloxacin versus ciprofloxacin in lower respiratory tract infections: a randomised, double-blind trial. J. Antimicrob. Chemother. 1992;30:89–100
  19. Shah PM, Maesen FPV, Dolmann A, Vetter N, Fiss E, Wesch R. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study. J. Antimicrob. Chemother. 1999;43:529–539
  20. Georgopoulos A, Borek M, Ridl W. and the Amoxycillin Bronchitis Study Group. Randomized, double-blind, double-dummy study comparing the efficacy and safety of amoxycillin 1g bd with amoxycillin 500mg tds in the treatment of acute exacerbation of chronic bronchitis. J. Antimicrob. Chemother. 2001;47:67–76
  21. Masterton RG, Burley CJ. The Study Group. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbations of chronic bronchitis. Int. J. Antimicrob. Agents. 2001;18:503–512
  22. Niederman MS, Mandell LA, Anzueto A, et al.  Guidelines for the management of adults with community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 2001;163:1730–1754
  23. Marston BJ, Plouffe JF, File TM, et al.  Incidence of community-acquired pneumonia requiring hospitalizations: results of a population-based active surveillance study in Ohio. Community-Based Pneumonia Incidence Group. Arch. Intern. Med. 1997;157:1709–1718
  24. Macfarlane J, Boswell T, Douglas G, et al.  BTS guidelines for the management of community-acquired pneumonia in adults. Thorax. 2001;56(Suppl. IV):iv1–iv64
  25. American Thoracic Society. Chronic bronchitis, asthma and pulmonary emphysema. A statement by the Committee on Diagnostic Standards for Nontuberculous Respiratory Diseases. Am Rev Respir Dis 85;1962:762–68.
  26. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987;106:196–204
  27. Burrows B, Lebowitz MD. Quantitative relationships between cigarette smoking and chronic productive cough. Int. J. Epidemiol. 1977;6:107–113
  28. Xu X, Christiani DC, Dockery DW, Warg L. Exposure-response relationships between occupational exposures and chronic illness: a community-based study. Am. Rev. Respir. Dis. 1992;146:413–418
  29. Burge PS. Occupation and chronic obstructive pulmonary disease (COPD). Eur. Respir. J. 1994;7:1032–1034
  30. Matsuse T, Hayashi S, Kuwano K, et al.  Latent adenoviral infection in the pathogenesis of chronic airways obstruction. Am. Rev. Respir. Dis. 1992;146:177–184
  31. Middleton AM, Dowling RB, Mitchell JL, et al.  Haemophilus parainfluenzae infection of respiratory mucosa. Respir. Med. 2003;97:375–381
  32. Mitchell JL, Hill SL. Immune response to Haemophilus parainfluenzae in patients with chronic obstructive lung disease. Clin. Diagn. Lab. Immunol. 2000;7:25–30
  33. Eller J, Ede A, Schaberg R, et al.  Infective exacerbations of chronic bronchitis. Relationship between bacteriologic etiology and lung function. Chest. 1998;122:1542–1548
  34. Miravitlles M, Espinosa C, Fernández-Laso E, et al.  Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest. 1999;116:40–46
  35. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest. 2000;117:380S–385S
  36. Mogulkoc N, Karakurt S, Isalska B, et al.  Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am. J. Respir. Crit. Care Med. 1999;160:349–353
  37. Lieberman D, Lieberman D, Ben-Yaakov M, et al.  Infectious etiologies in acute exacerbation of COPD. Diagn. Microbiol. Infect. Dis. 2001;40:95–102
  38. Cole P. Host-microbe relationships in chronic respiratory infection. Respiration. 1989;55(Suppl. 1):5–8
  39. Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1992;146:1067–1083
  40. Seemungal TAR, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000;161:1608–1613
  41. Wilson R, Schentag JJ, Ball P, Mandell L. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin. Ther. 2002;24:639–652
  42. Sethi S, Evans N, Grant BJB, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 2002;347:465–471
  43. Anthonisen NR. Bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 2002;347:526–527
  44. Ball P. Quinolone generations: natural history or natural selection. J. Antimicrob. Chemother. 2000;46(Topic T1):17–24
  45. King A, May J, French G, Phillips I. Comparative in vitro activity of gemifloxacin. J. Antimicrob. Chemother. 2000;45(Suppl. S1):1–12
  46. Waites KB, Crabb DM, Duffy LB. Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against Mycoplasma pneumoniae. Int. J. Antimicrob. Agents. 2003;21:574–577
  47. Blondeau JM. A review of clinical trials with fluoroquinolones with an emphasis on new agents. Exp. Opin. Invest. Drugs. 2000;9:383–413
  48. Wise R, Honeybourne D. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Eur. Respir. J. 1999;14:221–229
  49. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 1998;26:1–10
  50. File TM. Iannini PB. A profile of gemifloxacin, a new respiratory fluoroquinolone. Today’s Therapeutic Trends. 2003;21:415–435
  51. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin. Microbiol. Infect. 2001;7:589–596
  52. Morrissey I, George JT. Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones. J. Antimicrob. Chemother. 2000;45(Suppl. 1):101–106
  53. Heaton VJ, Ambler JE, Fisher LM. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrob. Agents Chemother. 2000;44:3112–3117
  54. Gillespie SH, Voelker LL, Ambler JE, Traini C, Dickens A. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation. Microb. Drug Resist. 2003;9:17–24
  55. Gillespie SH, McHugh TD. The biological cost of antimicrobial resistance. Trends Microbiol. 1997;5:337–339
  56. Bouma JE, Lenski RE. Evolution of a bacteria/plasmid association. Nature. 1988;335:313–351
  57. Billington OJ, McHugh TD, Gillespie SH. Physiological cost of rifampicin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1999;43:1866–1869
  58. Sefton AM, Maskell JP, Williams JD. Selection of resistant variants of respiratory pathogens by quinolones. Int. J. Antimicrob. Agents. 1999;12:129–134
  59. Gillespie SH, Voelker LL, Dickens A. Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microb. Drug Resist. 2002;8:79–84
  60. Fisher LM, Gould KA, Pan XS, Patel S, Heaton VJ. Analysis of dual active fluoroquinolones in Streptococcus pneumoniae. J. Antimicrob. Agents. 2003;52:312–313
  61. Heaton VJ, Ambler JE, Fisher LM. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. Antimicrob. Agents Chemother. 2000;44:3112–3117
  62. Frisch AW, Tripp JT, Barrett CD, Pidgeon BE. The specific polysaccharide content of pneumonic lungs. J. Exp. Med. 1942;76:505–510
  63. Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob. Agents Chemother. 2002;46:267–274
  64. Davies TA, Kelly LM, Pankuch GA, Credito KL, Jacobs MR, Appelbaum PC. Antipneumococcal activities of gemifloxacin compared to those of nine other agents. Antimicrob. Agents Chemother. 2000;44:304–310
  65. Davies TA, Kelly LM, Hoellman DB, et al.  Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob. Agents Chemother. 2000;44:633–639
  66. McCloskey L, Moore T, Niconovich N, et al.  In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA. J. Antimicrob. Chemother. 2000;45(Suppl. 1):13–21
  67. Lewin CS, Morrissey I, Smith JT. The mode of action of quinolones: the paradox inactivity of low and high concentrations and activity in the anaerobic environment. Eur. J. Clin. Microbiol. Infect. Dis. 1991;10:240–248
  68. Morrissey I, Smith JT. Bactericidal activity of the new 4-quinolones DU-6859a and DV-7751a. J. Med. Microbiol. 1995;43:4–8
  69. Morrissey I. Bactericidal activity of trovafloxacin (CP-99,219). J. Antimicrob. Chemother. 1996;38:1061–1066
  70. Morrissey I, Clark S, Mathias I. The bactericidal activity of gemifloxacin (SB-265805). J. Med. Microbiol. 2000;49:841–844
  71. Morrissey I, George JT. Bactericidal activity of gemifloxacin and other quinolones against Streptococcus pneumoniae. J. Antimicrob. Chemother. 2000;45(Suppl. 1):107–110
  72. Gemifloxacin (Factive®) Prescribing Information July 2003, Genesoft Pharmaceuticals, South San Francisco, CA.
  73. Andrews JM, Honeybourne D, Jevons G, Brenwald NP, Cunningham B, Wise R. Concentrations of levofloxacin (HR355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 1997;40:573–577
  74. Soman A, Honeybourne D, Andrews J, Jevons G, Wise R. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 1999;44:835–838
  75. Zhanel GG, Palatnick L, Nichol KA, Bellyou T, Low DE, Hoban DJ. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 2003;47:1867–1874
  76. Schito GC, Debbia EA, Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the Alexander Project. J. Antimicrob. Chemother. 2000;46(Topic T1):3–9
  77. Baquero F, Garcı́a-Rodrı́guez JA, Garcı́a de Lomas J, Aguilar L. and the Spanish Surveillance Group for Respiratory Pathogens. Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996–1997) multicenter surveillance study. Antimicrob. Agents Chemother. 1999;43:357–359
  78. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999–2000, including a comparison of resistance rates since 1994–1995. Antimicrob. Agents Chemother. 2001;45:1721–1729
  79. Felmingham D, Reinert RR, Hirakata Y, Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J. Antimicrob. Chemother. 2002;50(Suppl. S1):25–37
  80. Karlowsky JA, Draghi DC, Thornsberry C, Jones ME, Critchley IA, Sahm DF. Antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in two successive respiratory seasons in the US. Int. J. Antimicrob. Agents. 2002;20:76–85
  81. Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN. and the Alexander Project Group. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 2003;52:229–246
  82. Ho PL, Yung RWH, Tsang DNC, et al.  Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J. Antimicrob. Chemother. 2001;48:659–665
  83. Chen DK, McGeer A, De Azavedo JC, Low DE. The Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 1999;341:233–239
  84. Pankuch GA, Bozdogan B, Nagai K, et al.  Incidence, epidemiology and characteristics of quinolone-nonsusceptible Streptococcus pneumoniae in Croatia. Antimicrob. Agents Chemother. 2002;46:2671–2675
  85. Linares J, de la Campa AG, Pallares R. Fluoroquinolone resistance in Streptococcus pneumoniae. N. Engl. J. Med. 1999;341:1546–1548
  86. Davidson R, Cavalcanti R, Brunton JL, et al.  Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. 2002;346:747–750
  87. Hoban DJ, Bouchillon SK, Karlowsky JA, et al.  A comparative in vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America and South America. Antimicrob. Agents Chemother. 2000;44:3008–3011
  88. Pérez-Trallero E, Garcı́a-Rey C, Martı́n-Sánchez AM, et al.  Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain. Antimicrob. Agents Chemother. 2002;46:2665–2667
  89. Lim S, Bast D, McGeer A, de Azavedo J, Low DE. Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg. Infect. Dis. 2003;9:833–837
  90. Lode H, File TM, Mansell L, et al.  Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin. Ther. 2002;24:1915–1936
  91. File TM, Schlemmer B, Garau J, Cupo M, Young C. 049 Clinical Study Group. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J. Antimicrob. Chemother. 2001;48:67–74
  92. Ball P, File TM, Twynholm M, Henkel T. Efficacy and safety of gemifloxacin 320mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. Int. J. Antimicrob. Agents. 2001;18:19–27
  93. Leophonte P, File T, Feldman CA. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid tid for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med, submitted for publication.
  94. Santos J, Aguilar L, Garcia-Mendez E, et al.  Clinical characteristics and response to newer quinolones in Legionella pneumonia: a report of 28 cases. J. Chemother. 2003;15:461–465
  95. Wilson R, Langan C, Ball P, Bateman K, Pypstra R. Gemifloxacin 207 Clinical Study Group. Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respir. Med. 2003;97:242–249
  96. Wilson R, Schentag JJ, Ball P, Mandell L. 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbation of chronic bronchitis and long-term clinical outcomes. Clin. Ther. 2002;24:639–652
  97. Finch R, Schürmann D, Collins O, et al.  Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob. Agents Chemother. 2002;46:1746–1754
  98. Lim WS, van der Eerden MM, Laing R. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–382
  99. Mandell LA, Bartlett JG, Dowell SF, File TM, Musher DM, Whitney C, et al.  Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompromised adults. Clin. Infect. Dis. 2003;37:1405–1433
  100. Ball P, Wilson R, Mandell L, Brown J, Henkel T. 069 Clinical Study Group. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomized, double-blind comparison with trovafloxacin. J. Chemother. 2001;13:288–298
  101. File T, Schlemmer B, Garau J, Lode H, Lynch S, Young C. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study group. J. Chemother. 2000;12:314–325
  102. Halpern MT, Palmer CS, Zodet M, Kirsch J. Cost-effectiveness of gemifloxacin: results from the GLOBE study. Am. J. Health Syst. Pharm. 2002;59:1357–1365
  103. Peric M, Bozdogan B, Jacobs MR, Appelbaum PC. Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. Antimicrob. Agents Chemother. 2003;47:1017–1022
  104. Wise R. The development of new antimicrobial agents. BMJ. 2003;317:643–644
  105. Burley CJ, Tillotson GS. Antimicrobial resistance: can we see the wood for the trees. Lancet. Infect. Dis. 2003;3:125–126
  106. Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest. 2000;117:1345–1352
  107. Miravitlles M, Murio C, Guerrero T, Gisbert R. For the DAFNE Study Group. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002;121:1449–1455
  108. Destache CJ, Dewan N, O’Donohue WJ, Campbell C, Angelillo VA. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 1999;43(Suppl. A):107–113
  109. Spencer S, Jones PW. For the GLOBE Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003;58:589–593

PII: S0924-8579(04)00091-3

doi: 10.1016/j.ijantimicag.2004.02.017

International Journal of Antimicrobial Agents
Volume 23, Issue 6 , Pages 533-546 , June 2004

Article Tools

* Image Usage & Resolution